ESMO Virtual Plenary: February 2023

Airs on 16 February 2023 at 18:30 CET
- Start date
- 16 Feb 2023
- End date
- 17 Feb 2023
- Location
- Virtual Meeting
- Live on
- 16 Feb 2023 at 18:30 CET
Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
Thursday, 16 February 2023 |
Friday, 17 February 2023 |
---|---|
18:30-19:30 CET |
13:00-14:10 CET |
Programme
Welcome and introduction, Scientific background and context Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study Critical analysis and perspectives (ESMO) AACR expert commentary Discussion and Q&A (i) |
Programme
Virtual Plenary Expert Insights: Webcast of 16 February presentations, Discussion and Q&A (ii) Chair: Kei Muro, Aichi Cancer Center Hospital, Nagoya, Japan Sun Young Rha, Yonsei University, Seoul, Republic of Korea Elizabeth Smyth, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK Matthew Chau Hsien Ng, National Cancer Centre Singapore, Singapore Li-Tzong Chen, National Health Research Institutes, Tainan City, Taiwan |